|Series C, 6/10 |
ARCH Venture Partners
|Venture Round, 10/11 ||$47.3M|
|Series D, 2/12 |
|Debt, 10/11 ||$4.75M|
BIND Biosciences, Inc. operates as a biopharmaceutical company and develops and commercializes therapeutic targeted nanoparticles for the treatment of cancer, inflammatory, infectious, and cardiovascular diseases. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.